Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine
出版年份 2021 全文链接
标题
Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine
作者
关键词
-
出版物
Frontiers in Immunology
Volume 12, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2021-09-29
DOI
10.3389/fimmu.2021.742914
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
- (2021) Zhiwei Wu et al. LANCET INFECTIOUS DISEASES
- Risk and course of SARS-CoV-2 infection in patients treated for hypothyroidism and hyperthyroidism
- (2021) Thomas H Brix et al. Lancet Diabetes & Endocrinology
- SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates
- (2021) Nikolaos C. Kyriakidis et al. npj Vaccines
- Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
- (2021) David S. Khoury et al. NATURE MEDICINE
- Vaccine Breakthrough Infections with SARS-CoV-2 Variants
- (2021) Ezgi Hacisuleyman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Symptoms and symptom clusters associated with SARS-CoV-2 infection in community-based populations: Results from a statewide epidemiological study
- (2021) Brian E. Dixon et al. PLoS One
- Genomic survey of SARS-CoV-2 vaccine breakthrough infections in healthcare workers from Kerala, India
- (2021) Beena Philomina J et al. JOURNAL OF INFECTION
- Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile
- (2021) Alejandro Jara et al. NEW ENGLAND JOURNAL OF MEDICINE
- Covid-19 Breakthrough Infections in Vaccinated Health Care Workers
- (2021) Moriah Bergwerk et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evidence for antibody as a protective correlate for COVID-19 vaccines
- (2021) Kristen A. Earle et al. VACCINE
- Case Study of Two Post Vaccination SARS-CoV-2 Infections with P1 Variants in CoronaVac Vaccinees in Brazil
- (2021) Cassia F. Estofolete et al. Viruses-Basel
- An interactive web-based dashboard to track COVID-19 in real time
- (2020) Ensheng Dong et al. LANCET INFECTIOUS DISEASES
- A Novel Coronavirus from Patients with Pneumonia in China, 2019
- (2020) Na Zhu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular Disease and Use of Renin-Angiotensin System Inhibitors in COVID-19
- (2020) Chia Siang Kow et al. American Journal of Cardiovascular Drugs
- Inflammatory Response Cells During Acute Respiratory Distress Syndrome in Patients With Coronavirus Disease 2019 (COVID-19)
- (2020) Yulin Zhang et al. ANNALS OF INTERNAL MEDICINE
- Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals
- (2020) Alba Grifoni et al. CELL
- Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19
- (2020) Mingfeng Liao et al. NATURE MEDICINE
- Risk of COVID‐19 for patients with obesity
- (2020) Radwan Kassir Obesity Reviews
- Gender Differences in Patients With COVID-19: Focus on Severity and Mortality
- (2020) Jian-Min Jin et al. Frontiers in Public Health
- Clinical features of COVID-19 in elderly patients: A comparison with young and middle-aged patients
- (2020) Kai Liu et al. JOURNAL OF INFECTION
- Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
- (2020) Pedro M Folegatti et al. LANCET
- A minimal common outcome measure set for COVID-19 clinical research
- (2020) John C Marshall et al. LANCET INFECTIOUS DISEASES
- Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults
- (2020) Mark J. Mulligan et al. NATURE
- SARS-CoV-2 vaccines in development
- (2020) Florian Krammer NATURE
- Multi-Omics Resolves a Sharp Disease-State Shift between Mild and Moderate COVID-19
- (2020) Yapeng Su et al. CELL
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
- (2020) Fernando P. Polack et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
- (2020) Yanjun Zhang et al. LANCET INFECTIOUS DISEASES
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now